Astellas Pharma CEO Says Confident of Iveric Bio Drug Approval

The video discusses strategic purposes for acquiring Everson and developing ACP for geographic atrophy, pending FDA approval. It highlights the company's capabilities in ophthalmology, including R&D and commercial efforts. The potential market impact of ACP is analyzed, especially in light of Xtandi's patent expiry. The focus on global markets, particularly the US, and key therapeutic areas like immune oncology and cell therapy is emphasized. The growth strategy includes both organic development and potential acquisitions, depending on the internal pipeline and competitive landscape.

What percentage of the company's revenue comes from outside Japan, and why is this significant?

What factors will influence whether the company pursues organic growth or acquisitions in the future?